Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Reactive oxygen species (ROS)–mitochondrial dysfunction–autophagy axis is a complex biological signaling network that integrates cellular stress sensing with organelle quality control. In this axis, excessive ROS—primarily generated as byproducts of the mitochondrial electron transport chain—induce oxidative damage to mitochondrial proteins, lipids, and DNA, leading to a loss of mitochondrial membrane potential and further ROS leakage (Murphy, 2009, Biochem J, PMID: 19128243). To prevent the accumulation of these dysfunctional organelles and subsequent apoptosis, the cell activates autophagy, specifically a selective form called mitophagy, which is often mediated by the PINK1/Parkin pathway or BNIP3/NIX receptors (Youle & Narendra, 2011, Nat Rev Mol Cell Biol, PMID: 21179060). This axis plays a dual role in human pathology: while its impairment contributes to the accumulation of damaged mitochondria in neurodegenerative diseases like Parkinson's, its overactivation can promote the survival of cancer cells under nutrient-deprived or hypoxic conditions (Scherz-Shouval & Elazar, 2011, Trends Biochem Sci, PMID: 21145745). Therapeutic strategies targeting this axis include the use of mitochondria-targeted antioxidants like MitoQ to quench ROS, or autophagy modulators like Rapamycin and Metformin to restore homeostatic clearance of damaged mitochondria (Li et al., 2015, Autophagy, PMID: 25906140).
Modulation of oxidative stress levels, stabilization of mitochondrial membrane potential, and regulation of autophagic flux via mTOR or AMPK pathways to maintain cellular proteostasis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reactive oxygen species–mitochondrial dysfunction–autophagy axis (ROS–mitochondrial dysfunction–autophagy axis).